Skip to content

Publications

Welcome to our Publications Page, where we bring together a curated collection of our peer-reviewed scientific research. This space showcases work that spans our therapy areas and reflects our ongoing dedication to advancing knowledge and driving innovation.

Category Title Date Publication
Manuscript Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion (opens in a new tab) August 2026 mAbs
Poster Effects of gamgertamig (OM336), a B cell maturation antigen (BCMA) x CD3 T cell engager, in a patient with active antiphospholipid antibody syndrome and concurrent autoimmune thrombocytopenia (opens in a new tab) July 2026 International Society on Thrombosis and Haemostasis (ISTH)
Abstract Gamgertamig (OM336), a novel B cell maturation antigen (BCMA) x CD3 T cell engager antibody, ameliorates disease in patients with warm or cold autoimmune hemolytic anemia (AIHA) (opens in a new tab) June 2026 European Hematology Association (EHA)
Manuscript Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies (opens in a new tab) April 2026 ScienceDirect
Poster Trial in progress: A Phase 1b, open-label, multiple ascending dose study of gamgertamig (OM336/CM336), a novel BCMAxCD3 T cell engager, in patients with relapsed/refractory autoimmune cytopenias (NCT07083960) (opens in a new tab) June 2025 American Society of Hematology (ASH)
Poster OM336, a B cell maturation antigen (BCMA) targeting T cell engager antibody, demonstrates initial safety and efficacy in the treatment of relapsed/refractory multiple myeloma (R/R MM) (opens in a new tab) June 2025 European Hematology Association (EHA)
Manuscript BCMA-targeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy (opens in a new tab) June 2025 The New England Journal of Medicine (NEJM)